EN DE
STOCK COMPARISON

Enwei Pharmaceutical Co. Ltd. A vs Jiangsu Hengrui Medicine Co: Fair Value & Quality

Both stocks run through our valuation models. Here is how Enwei Pharmaceutical Co. Ltd. A (301331) and Jiangsu Hengrui Medicine Co (600276) compare, as of Aug 11, 2026.

As of Aug 11, 2026, Fair Value Calculator sees Enwei Pharmaceutical Co. Ltd. A as the less overvalued of the two: Enwei Pharmaceutical Co. Ltd. A trades at ¥21.61 versus a fair value of ¥11.11 (-49%), while Jiangsu Hengrui Medicine Co trades at ¥54.18 versus ¥25.94 (-52%).
Enwei Pharmaceutical Co. Ltd. A
301331.SHE · CNY · Health Care
-49%
upside to fair value
overvalued
Price¥21.61
Fair Value¥11.11
Quality65/100
Jiangsu Hengrui Medicine Co
600276.SHG · CNY · Health Care
-52%
upside to fair value
overvalued
Price¥54.18
Fair Value¥25.94
Quality66/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Enwei Pharmaceutical Co. Ltd. AJiangsu Hengrui Medicine Co
Valuation
46.8×P/E (TTM)43.6×
2.52×P/S (TTM)10.84×
2.06×P/B5.76×
17.9×EV/EBITDA33.0×
PEG0.93×
3.1%Dividend yield0.4%
¥0.68Dividend per share¥0.20
Profitability
5%Net margin25%
7%Operating margin32%
4%Return on equity15%
2%Return on assets9%
Growth
-11%Revenue growth (YoY)13%
9.2%Avg. growth/yr (3Y)13.9%
7.3%Avg. growth/yr (5Y)2.5%
Balance & size
$329MMarket cap$52B
healthyGrowth qualityhealthy

Jiangsu Hengrui Medicine Co leads: 5 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Enwei Pharmaceutical Co. Ltd. Aof which business quality 65 · market factors 26 Jiangsu Hengrui Medicine Coof which business quality 68 · market factors 47
ProfitabilityMargins and returns on capital today
37
63
Quality GrowthAre margins and returns improving?
44
41
CashflowEarnings quality: real cash, not paper profit
52
82
Fin. StrengthBalance sheet, leverage, solvency risk
96
100
InvestmentDisciplined investing over empire-building
87
27
Low VolatilityCalm price path (market factor)
66
78
MomentumPrice trend over the last 3–12 months (market factor)
12
37
52W MomentumDistance to the 52-week high (market factor)
2
29
Net IssuanceBuybacks instead of dilution
83
64

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Enwei Pharmaceutical Co. Ltd. A

DCF Models¥13.03
Earnings-Based¥6.10
Multiples¥11.18
Asset-Based¥6.99
Growth DCF¥12.08
Economic Profit¥8.15
Growth Earnings¥10.05

24 of 24 models see the stock below the current price.

Jiangsu Hengrui Medicine Co

DCF Models¥37.78
Earnings-Based¥21.29
Dividend Discount¥3.82
Multiples¥23.65
Asset-Based¥6.44
Growth DCF¥39.88
Economic Profit¥18.21
Growth Earnings¥30.99

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Enwei Pharmaceutical Co. Ltd. A
Bear ¥8.33Fair Value ¥11.11Bull ¥13.88
¥21.61 = current price (white tick)
Jiangsu Hengrui Medicine Co
Bear ¥19.95Fair Value ¥25.94Bull ¥40.28
¥54.18 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Enwei Pharmaceutical Co. Ltd. A · Health Care

Quality score65 · Top 25%
Fair value upside-49% · below median

Jiangsu Hengrui Medicine Co · Health Care

Quality score66 · Top 25%
Fair value upside-52% · below median

Bottom line

As of Aug 11, 2026, Fair Value Calculator sees Enwei Pharmaceutical Co. Ltd. A as the less overvalued of the two: Enwei Pharmaceutical Co. Ltd. A trades at ¥21.61 versus a fair value of ¥11.11 (-49%), while Jiangsu Hengrui Medicine Co trades at ¥54.18 versus ¥25.94 (-52%).

Jiangsu Hengrui Medicine Co has the higher quality score (66/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.